Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Osama E. Rahma, Darren W.T. Lim, Ravit Geva, Toshikiko Doi, A. Xyrafas, Philippe L. Bedard, Jennifer Marie Mataraza, Alexander M. Lesokhin, Javier Otero, Tira Jing Ying Tan, Angad P Singh, Xinhui Chen, Jason J. Luke, Lisa Nardi, Sarina Anne Piha-Paul, Cinta Hierro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Scientia
Journal for Immunotherapy of Cancer
Scientia
BackgroundGWN323 is an IgG1 monoclonal antibody (mAb) against the glucocorticoid-induced tumor necrosis factor receptor-related protein. This first-in-human, open-label phase I/Ib study aimed to investigate the safety and tolerability and to identify
Autor:
Jeffrey R. Infante, Patrick Schöffski, Michael S. Gordon, Alain Ravaud, Manish Agrawal, John Allan Ellerton, Juliane Manitz, Manish R. Patel, Mary Ruisi, Andrea B. Apolo, Matthew H. Taylor, Luc Dirix, Ding Wang, Keun Wook Lee, Raid Aljumaily, Gregory Pennock, Theodore Gourdin, J.L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAnti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD
Autor:
Marie-Anne Damiette Smit, Manish A. Shah, Jeanne Tie, David P. Ryan, R. Donald Harvey, Victor Moreno, Dirk Jäger, Emilliano Calvo Aller, Neelesh Soman, James M. Cleary, William Jeffery Edenfield, Michael Boyer, Annemie Rutten, Gloria Juan, Kyriakos P. Papadopoulos, Erik Rasmussen, Dirk Nagorsen, Hansen Wong, Anthony J. Olszanski, Albiruni Ryan Abdul Razak, Nehal Lakhani
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundTo determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors.Patients and methodsPatients had advanced,
Autor:
Karen Kelly, Dongli Zhou, Jaafar Bennouna, Franklin Chen, Guy Jerusalem, John C. Morris, Ding Wang, Claire F. Verschraegen, Marcis Bajars, Edward F. McClay, Neru Munshi, David R. Spigel, Hans Juergen Grote, Janice M. Mehnert, Matthew H. Taylor, James L. Gulley, Nicholas Iannotti, Charles H. Redfern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
IntroductionAvelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We
Autor:
Haiying Sun, Marcus O. Butler, Sunil Sharma, Jason E. Faris, Hongqian Wu, Jennifer Marie Mataraza, Andrea Varga, Todd M. Bauer, Jan H.M. Schellens, Antonio P. Silva, Justin F. Gainor, Chia-Chi Lin, Scott Cameron, Matthew H. Taylor, Aung Naing, Hans Gelderblom, Maria Ochoa de Olza, Patrick M. Forde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, 8(1). BMJ PUBLISHING GROUP
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, 8(1). BMJ PUBLISHING GROUP
Journal for Immunotherapy of Cancer
BackgroundSpartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2. This phase 1/2 study was designed to assess the safety, pharmacokinetics, and preliminary efficacy